August 30, 2014 8:51 PM ET

Pharmaceuticals

Company Overview of Rimonyx Pharmaceuticals, Ltd.

Company Overview

Rimonyx Pharmaceuticals, Ltd. engages in the discovery and development of drugs targeted at glycosaminoglycan and protein interactions. Its RX-111, an orally delivered small molecule drug for inflammatory bowel disease, is slated to enter Phase I clinical trials in the second quarter of 2005. Rimonyx Pharmaceuticals was founded by Paul Gregor in 2002. The company is based in Ness-Ziona, Israel.

Kiryat Weizmann Science Park

Sapir Street 7

Ness-Ziona,  70400

Israel

Founded in 2002

Phone:

972 8 940 4593

Fax:

972 8 940 0917

Key Executives for Rimonyx Pharmaceuticals, Ltd.

Founder
Director of Medicinal Chemistry
Vice President of R & D
Scientific Advisor
Business Advisor and Director
Age: 63
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Chiasma (Israel) ltd. Middle East/Africa
OMER Therapeutics Ltd. Middle East/Africa
Target-in Ltd. Middle East/Africa
Coeruleus Ltd. Middle East/Africa
Mindset BioPharmaceuticals Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Rimonyx Pharmaceuticals, Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.